Literature DB >> 23071186

TrACEing angiotensin II type 1 to right ventricular hypertrophy: are the "sartans" a viable course to treating pulmonary arterial hypertension?

Daniel Ranayhossaini, Patrick J Pagano.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23071186      PMCID： PMC4522859          DOI： 10.1164/rccm.201208-1480ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  18 in total

Review 1.  Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling.

Authors:  Imad Al Ghouleh; Nicholas K H Khoo; Ulla G Knaus; Kathy K Griendling; Rhian M Touyz; Victor J Thannickal; Aaron Barchowsky; William M Nauseef; Eric E Kelley; Phillip M Bauer; Victor Darley-Usmar; Sruti Shiva; Eugenia Cifuentes-Pagano; Bruce A Freeman; Mark T Gladwin; Patrick J Pagano
Journal:  Free Radic Biol Med       Date:  2011-06-14       Impact factor: 7.376

2.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.

Authors:  M Humbert; S Maître; F Capron; B Rain; D Musset; G Simonneau
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

3.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

Review 4.  Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.

Authors:  Brian S Zuckerbraun; Patricia George; Mark T Gladwin
Journal:  Cardiovasc Res       Date:  2010-12-22       Impact factor: 10.787

Review 5.  Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.

Authors:  Carl Eriksson; Anders Gustavsson; Thomas Kronvall; Curt Tysk
Journal:  J Gastrointestin Liver Dis       Date:  2011-03       Impact factor: 2.008

6.  Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.

Authors:  Paul R Forfia; Stephen C Mathai; Micah R Fisher; Traci Housten-Harris; Anna R Hemnes; Hunter C Champion; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

7.  Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

Authors:  D L Wessel; I Adatia; T M Giglia; J E Thompson; T J Kulik
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

8.  Captopril in primary pulmonary hypertension.

Authors:  C V Leier; D Bambach; S Nelson; J B Hermiller; P Huss; R D Magorien; D V Unverferth
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

9.  Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats.

Authors:  Muneyoshi Okada; Toshiyuki Harada; Ryuta Kikuzuki; Hideyuki Yamawaki; Yukio Hara
Journal:  J Pharmacol Sci       Date:  2009-10-06       Impact factor: 3.337

10.  Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension.

Authors:  Wendy K Chung; Liyong Deng; J Sheila Carroll; Nicole Mallory; Beverly Diamond; Erika Berman Rosenzweig; Robyn J Barst; Jane H Morse
Journal:  J Heart Lung Transplant       Date:  2009-04       Impact factor: 10.247
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.